The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

By A. Kotschy, Z. Szlávik, J. Murray, James Davidson, A. Maragno, G. L. Toumelin-Braizat, Maïa Chanrion, G. Kelly, Jia-Nan Gong, Donia M. Moujalled and 43 more. Nature, 2016

971 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/804d41f048a7386a3e6b3fcd1589511de3fabcd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guido Kroemer
2. Douglas R. Green
3. L. Galluzzi
4. Beth Levine
5. Simone Fulda
6. D. Tang
7. Junying Yuan
8. D. Klionsky

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. D. Tang
4. Scott J. Dixon
5. L. Zitvogel
6. M. Conrad
7. Moshe Oren
8. Christoph Borner

Citations in the corpus

• Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018, background): “Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinic”